Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

$35.63 +0.04 (+0.11%)

(As of 12/20/2024 05:31 PM ET)

Ionis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
1

Hold
5

Buy
13

Based on 19 Wall Street analysts who have issued ratings for Ionis Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 1 has given a sell rating, 5 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for IONS.

Consensus Price Target

$60.65
70.21% Upside

According to the 19 analysts' twelve-month price targets for Ionis Pharmaceuticals, the average price target is $60.65. The highest price target for IONS is $77.00, while the lowest price target for IONS is $37.00. The average price target represents a forecasted upside of 70.21% from the current price of $35.63.

Get the Latest News and Ratings for IONS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Ionis Pharmaceuticals and its competitors.

IONS Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	12 Buy rating(s)	12 Buy rating(s)	12 Buy rating(s)	6 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$60.65	$60.65	$60.68	$48.36
Forecasted Upside	70.21% Upside	78.32% Upside	45.07% Upside	-5.53% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Your bank is lying to you. (Ad)

You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.

View the best savings account rates here

IONS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IONS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ionis Pharmaceuticals Stock vs. The Competition

Type	Ionis Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.68	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	70.21% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent IONS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/20/2024	Needham & Company LLC 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00	+68.59%
12/20/2024	William Blair 2 of 5 stars		Reiterated Rating	Outperform
11/14/2024	Piper Sandler 2 of 5 stars		Lower Target	Overweight ➝ Overweight	$65.00 ➝ $62.00	+65.33%
11/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$82.00 ➝ $77.00	+95.38%
10/9/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$70.00 ➝ $65.00	+69.40%
9/26/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$70.00 ➝ $70.00	+70.77%
70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad) Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here <<
8/26/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$50.00 ➝ $55.00	+17.25%
8/2/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sell ➝ Sell	$33.00 ➝ $37.00	-24.40%
8/2/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$45.00 ➝ $51.00	+4.74%
8/2/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Biliouris Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$67.00 ➝ $60.00	+16.91%
7/24/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Foroohar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/24/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$53.00 ➝ $62.00	+22.94%
7/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$54.00 ➝ $59.00	+16.79%
7/23/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$67.00 ➝ $68.00	+34.36%
7/16/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underperform ➝ Buy	$29.00 ➝ $75.00	+57.66%
6/27/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$50.00 ➝ $53.00	+11.11%
6/14/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Pickering Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$44.00	+7.00%
4/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Peer Perform ➝ Outperform	$58.00	+35.42%
4/9/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$72.00 ➝ $75.00	+77.56%
11/3/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$45.00 ➝ $48.00	+9.76%
9/28/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Strong-Buy	$63.00	+36.19%
7/31/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$36.00 ➝ $60.00	+50.79%
5/4/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
2/23/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$34.00 ➝ $27.00	-26.63%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:25 AM ET.

IONS Forecast - Frequently Asked Questions

: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Ionis Pharmaceuticals is $60.65, with a high forecast of $77.00 and a low forecast of $37.00.
: 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 5 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IONS shares.
: According to analysts, Ionis Pharmaceuticals's stock has a predicted upside of 70.21% based on their 12-month stock forecasts.
: Ionis Pharmaceuticals has been rated by research analysts at Guggenheim, Needham & Company LLC, Piper Sandler, Royal Bank of Canada, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Ionis Pharmaceuticals less than other "medical" companies. The consensus rating score for Ionis Pharmaceuticals is 2.68 while the average consensus rating score for "medical" companies is 2.81. Learn more on how IONS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Your bank is lying to you. (Ad)

You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.

View the best savings account rates here

This page (NASDAQ:IONS) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target